Aplastic Anemia Life Expectancy: Prognosis and Survival

Life expectancy with aplastic anemia depends heavily on the severity of the disease, the patient’s age, and how quickly effective treatment begins. A young person with severe aplastic anemia who receives a matched sibling donor stem cell transplant now has a greater than 90% chance of long-term survival, while an older adult over 60 who cannot undergo transplant faces a five-year survival rate closer to 40%. These numbers represent a dramatic improvement over earlier decades, when the disease was frequently fatal within months, but they also highlight how wide the range of outcomes still is.

What Aplastic Anemia Actually Does

Aplastic anemia is a bone marrow failure disease. The marrow stops producing enough red blood cells, white blood cells, and platelets. In most cases the cause is autoimmune: the body’s own T cells attack and destroy the stem cells that are supposed to make new blood cells. Dysregulated immune cells, including cytotoxic T cells and natural killer cells, along with inflammatory signaling molecules like interferon-gamma and tumor necrosis factor-alpha, drive the destruction of these stem and progenitor cells.¹ The result is a marrow that looks empty under the microscope, and blood counts that drop to dangerously low levels.²

The immediate threat is not the anemia itself but what happens when blood counts are critically low. Without enough white blood cells, even a minor infection can become life-threatening. Without enough platelets, uncontrolled bleeding can occur. These complications are what drive early mortality, and their management has as much to do with survival as the definitive treatment chosen.

How Age and Disease Severity Shape Survival

Two factors matter more than anything else when estimating how long someone with aplastic anemia will live: age at diagnosis and how severe the disease is. A Swedish population-based study tracking patients diagnosed between 2000 and 2011 found stark differences across age groups. Five-year survival was about 91% for those diagnosed before age 40, dropped to roughly 71% for patients aged 40 to 59, and fell to about 38% for patients 60 and older.³ Very severe aplastic anemia, where neutrophil counts are profoundly low, was an independent risk factor for worse survival in that same analysis. Older patients face a double disadvantage: they tolerate aggressive treatments less well and are more vulnerable to the infections and bleeding that kill before treatment can work.⁴

In children, the picture is somewhat different but age still matters. A large U.S. institutional study found that pediatric patients diagnosed at older ages within childhood (especially the mid-teen years) had higher mortality risk than very young children. Other factors associated with worse outcomes in children included low platelet counts, being underweight at diagnosis, and male sex.⁵

Stem Cell Transplant as a Cure

For patients who have a matched sibling donor, a hematopoietic stem cell transplant (often called a bone marrow transplant) is the closest thing to a cure. Advances in how patients are prepared for transplant and in post-transplant care have pushed survival rates above 90% in children and young adults who receive a transplant from a matched sibling.⁶ A long-term follow-up study of transplant recipients found that 20-year survival was about 89% in patients who did not develop chronic graft-versus-host disease (GVHD), a complication where the donor’s immune cells attack the recipient’s tissues. For those who did develop chronic GVHD, 20-year survival was roughly 69%.⁷

That same study paints a detailed picture of life after transplant. All long-term survivors had normal blood counts. The majority returned to school or work within two years, and by 20 years that proportion reached about 90%. At least half preserved or regained fertility. Patients rated their quality of life as excellent and their symptoms as minimal. The main cloud over long-term transplant survivors was chronic GVHD, which drove most late deaths and complications including skin problems, cataracts, and lung disease.⁷ A small number of transplant survivors developed solid tumors years later, and one case report documented two subsequent cancers in a child who underwent transplant, reinforcing that transplant survivors need ongoing cancer surveillance.⁸

The catch is that only about 25 to 30% of patients have a matched sibling available. Transplants from unrelated donors or partially matched family members are increasingly used but carry higher complication rates, and outcomes vary more. Age is also a limiting factor: transplant is generally the first-choice treatment for younger patients with severe disease and a matched donor, while older patients or those without a donor are steered toward drug-based therapy.

Immunosuppressive Therapy and What Response Means for Survival

For patients who are not candidates for transplant, the standard treatment is immunosuppressive therapy (IST), typically a combination of antithymocyte globulin (ATG) and cyclosporine. The goal is to rein in the immune attack on the bone marrow so it can recover on its own. A landmark randomized trial found that horse ATG combined with cyclosporine produced a blood-count response in about 68% of patients by six months, with three-year overall survival around 96%.⁹ Rabbit ATG, an alternative formulation, performed substantially worse in that trial, with a 37% response rate and lower survival.

In children, though, the picture is less clear-cut. A large retrospective analysis found that response rates to horse and rabbit ATG were comparable at both three and six months, with around 55 to 60% responding by six months regardless of the formulation used.¹⁰

Whether or not a patient responds early is one of the single strongest predictors of long-term survival. In a study of over 100 patients treated with ATG and cyclosporine, those who achieved a hematologic response (meaning their blood counts recovered enough to no longer qualify as severe and they stopped needing transfusions) had five-year survival around 86%, compared to roughly 40% in non-responders. Early markers of a strong response, such as a rising platelet count above 50,000 within three months, predicted five-year survival above 90%.¹¹ This is why hematologists monitor blood counts closely in the first few months after starting IST: the trajectory matters enormously.

The Impact of Eltrombopag

One of the more significant recent advances is the addition of eltrombopag, a drug that stimulates the bone marrow to produce more blood cells, to standard immunosuppressive therapy. A randomized trial comparing standard IST alone versus IST with eltrombopag found that the combination roughly doubled response rates. At six months, about 68% of patients receiving the combination had responded, compared to 41% with IST alone. The median time to first response was also much shorter: about three months with the combination versus nearly nine months without it.¹² The rate of serious side effects was similar between the groups, meaning the benefit came without an obvious safety cost.

Because early response so strongly predicts survival, getting more patients to respond faster has real implications for life expectancy, even if the trial was not large enough to show a definitive survival difference on its own. Eltrombopag has been incorporated into first-line treatment at many centers, and additional work is ongoing to determine optimal dosing and duration.¹³

Infections as the Leading Killer

Before treatment has a chance to work, patients with severe aplastic anemia are profoundly vulnerable to infections. Invasive fungal infections, especially aspergillosis and candida, are the most feared. In one study, fungal infections accounted for about 55% of fatal infectious events. Even with antifungal therapy, invasive aspergillosis was associated with fatal pulmonary hemorrhage in the majority of cases. Overall, infection was responsible for about 62% of deaths observed during the study period.¹⁴ Another study from a major cancer center confirmed that all infection-related deaths in their cohort involved invasive fungal infections in patients who had prolonged severe drops in neutrophils (the white blood cells that fight bacteria and fungi).¹⁵

This is why supportive care during the initial treatment period is so critical. Prevention and management of bleeding, bacterial and fungal infections, and complications like iron overload from repeated transfusions all have a substantial impact on whether a patient survives long enough for definitive treatment to take effect.¹⁶ Patients diagnosed early and treated at specialized centers with robust supportive infrastructure tend to do better in part because the gap between diagnosis and treatment response is so dangerous.

Long-Term Risks After Successful Treatment

Surviving the initial crisis does not eliminate all risk. A proportion of patients treated with immunosuppressive therapy go on to develop clonal blood disorders, meaning the bone marrow that recovers may harbor genetic changes that lead to myelodysplastic syndrome (MDS) or, less commonly, acute myeloid leukemia (AML).¹⁷ In one study of children treated with IST, about 14% developed MDS over a follow-up period of up to roughly seven years. Prolonged use of granulocyte colony-stimulating factor (G-CSF, a drug sometimes given to boost white cell counts) and failure to respond to initial therapy were both risk factors.¹⁸

This risk of clonal evolution is one reason some specialists favor transplant when feasible: transplant replaces the damaged marrow entirely, whereas IST allows the original marrow to recover, genetic scars and all. For IST-treated patients, regular bone marrow monitoring is standard practice for years after treatment.

Relapse and Second-Line Treatment

Even among patients who respond well to IST, relapse is a real possibility. The immune attack on the marrow can return, sometimes years after initial treatment. When it does, patients face a choice between a second round of IST or proceeding to transplant. A Japanese study of children who relapsed after IST found that overall survival after second-line treatment was roughly 85% in those re-treated with IST and about 64% in those who went directly to transplant, though failure-free survival (meaning sustained remission without needing further intervention) was better with transplant.¹⁹

A more recent comparison in adults and older patients found similar overall five-year survival rates between the two approaches (about 80% for both), but transplant again produced better failure-free survival. Younger age at salvage transplant, specifically 35 or under, was the strongest predictor of good outcomes.²⁰ The practical takeaway is that relapse does not mean the situation is hopeless, but younger patients who relapse are often guided toward transplant for a more durable result.

The PNH Connection

A quirk of aplastic anemia biology is that many patients develop small populations of cells that carry the genetic signature of paroxysmal nocturnal hemoglobinuria (PNH), a related blood disorder. These PNH clones are actually associated with better outcomes, not worse. In a 20-year single-center study, patients who tested positive for PNH clones and were treated with IST had 100% five-year survival, compared to about 72% in PNH-negative patients. Among those who received transplants, PNH-positive patients also had lower rates of chronic GVHD. The size of the PNH clone did not seem to matter; even a small one carried the same favorable signal.²¹ The presence of a PNH clone may indicate that the disease is more strongly immune-driven and therefore more responsive to immunosuppressive treatment.

Quality of Life After Treatment

Survival statistics capture whether someone is alive, not how they feel. Studies that look beyond survival paint a more nuanced picture. One survey of patients who had responded to IST found that 83% still experienced fatigue as a persistent issue. Psychological and physical effects continued despite nominally successful treatment.²² A qualitative study from China that interviewed patients about their experiences identified declining physical capacity, mood changes tied to the stage of disease, shifts in self-image, and a sense of being a burden to family members as recurring themes.²³

The long-term transplant data mentioned earlier offers a counterpoint: those patients rated their quality of life highly, and most returned to fully functional lives. The difference may reflect the fact that transplant, when it succeeds, replaces the dysfunctional marrow entirely, whereas IST leaves patients dependent on an immune system that may only be partially suppressed and a marrow that may only partially recover. This is a genuine tension in the field: IST avoids the upfront risks of transplant but may leave patients in a less complete state of health long-term.

Hepatitis-Associated Aplastic Anemia

A small but recognized subset of aplastic anemia cases develops after a bout of hepatitis, often caused by a virus that standard hepatitis panels do not detect. This variant tends to be severe and aggressive. In a series published in the New England Journal of Medicine, seven of ten patients responded to intensive immunosuppressive treatment, but all three non-responders died within a year, two from transplant complications.²⁴ Individual case reports describe rapid deterioration to transfusion dependence and fatal sepsis within months of diagnosis.²⁵ The condition is treatable with the same approaches used for other forms of aplastic anemia, but the window for intervention is narrow, and outcomes appear worse than average when treatment fails.

Pregnancy and Aplastic Anemia

Aplastic anemia can first appear during pregnancy, or a woman with previously treated aplastic anemia may relapse while pregnant. Either scenario creates a high-risk situation for both mother and baby. A systematic review and meta-analysis found that maternal mortality in pregnancies affected by aplastic anemia was about 4%, with neonatal mortality around 7%. Roughly three-quarters of patients required blood transfusions during labor and delivery, and more than half delivered by cesarean section. Complications included postpartum hemorrhage in about 12% and fetal growth restriction in about 6%.²⁶ A case series review similarly found infections in about 23% and bleeding in about 26% of affected pregnancies, though about 57% of infants were reported healthy at birth.²⁷

Low hemoglobin and low platelet counts appear to be the primary drivers of obstetric complications in these pregnancies.²⁸ Management typically involves aggressive transfusion support and close collaboration between hematologists and obstetricians. Immunosuppressive drugs like cyclosporine have been used during pregnancy in some cases, but treatment decisions are individualized and complex. For women with aplastic anemia who are considering pregnancy, the timing relative to disease status and treatment response is a critical discussion to have with their care team.